Scholarlink

<p>The treatment of pancreatic ductal adenocarcinomas (PDAC) represents one of the greatest challenges in gastrointestinal oncology. Patients with PDAC are characterized by a mostly aggressive tumor biology associated with a profound resistance against cytostatic agents and have a poor prognosis with a mean survival of approximately 1 year. Although the use of immune checkpoint inhibitors (ICI) plays a central role in the treatment of a variety of solid neoplasms, the use of this revolutionary treatment principle on its own shows practically no clinical benefit in the vast majority of patients with advanced PDAC. With the exception of tumors with microsatellite instability, PDACs mostly show a low immunogenicity. In contrast to numerous other solid neoplasms, pancreatic carcinomas show a stroma-rich tumor environment, which contains a high proportion of immunosuppressive immune cells, such asregulatory T&#xa0;cells (Tregs), carcinoma-associated fibroblasts (CAFs) or myeloid-derived suppressor cells (MDSCs), that prevent an efficient effect of antitumor effector T cells and therefore makes the use of ICIs in PDACs inefficient. However, very recent developments show that a combination treatment of ICI and drugs that can elevate the immunogenicity of pancreatic cancer cells, possibly represent a meaningful approach to enable an effective use even in patients with advanced PDAC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aktuelle Entwicklungen der Immuntherapie beim Pankreaskarzinom

  • 期刊论文

  • 发表日期：

    2025年8月19日

查看全文
  • Volker Ellenrieder,
  • Alexander König

摘要

The treatment of pancreatic ductal adenocarcinomas (PDAC) represents one of the greatest challenges in gastrointestinal oncology. Patients with PDAC are characterized by a mostly aggressive tumor biology associated with a profound resistance against cytostatic agents and have a poor prognosis with a mean survival of approximately 1 year. Although the use of immune checkpoint inhibitors (ICI) plays a central role in the treatment of a variety of solid neoplasms, the use of this revolutionary treatment principle on its own shows practically no clinical benefit in the vast majority of patients with advanced PDAC. With the exception of tumors with microsatellite instability, PDACs mostly show a low immunogenicity. In contrast to numerous other solid neoplasms, pancreatic carcinomas show a stroma-rich tumor environment, which contains a high proportion of immunosuppressive immune cells, such asregulatory T cells (Tregs), carcinoma-associated fibroblasts (CAFs) or myeloid-derived suppressor cells (MDSCs), that prevent an efficient effect of antitumor effector T cells and therefore makes the use of ICIs in PDACs inefficient. However, very recent developments show that a combination treatment of ICI and drugs that can elevate the immunogenicity of pancreatic cancer cells, possibly represent a meaningful approach to enable an effective use even in patients with advanced PDAC.